首页> 美国卫生研究院文献>Frontiers in Microbiology >Fusion tags for protein solubility purification and immunogenicity in Escherichia coli: the novel Fh8 system
【2h】

Fusion tags for protein solubility purification and immunogenicity in Escherichia coli: the novel Fh8 system

机译:用于大肠杆菌中蛋白溶解度纯化和免疫原性的融合标签:新型Fh8系统

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Proteins are now widely produced in diverse microbial cell factories. The Escherichia coli is still the dominant host for recombinant protein production but, as a bacterial cell, it also has its issues: the aggregation of foreign proteins into insoluble inclusion bodies is perhaps the main limiting factor of the E. coli expression system. Conversely, E. coli benefits of cost, ease of use and scale make it essential to design new approaches directed for improved recombinant protein production in this host cell. With the aid of genetic and protein engineering novel tailored-made strategies can be designed to suit user or process requirements. Gene fusion technology has been widely used for the improvement of soluble protein production and/or purification in E. coli, and for increasing peptide’s immunogenicity as well. New fusion partners are constantly emerging and complementing the traditional solutions, as for instance, the Fh8 fusion tag that has been recently studied and ranked among the best solubility enhancer partners. In this review, we provide an overview of current strategies to improve recombinant protein production in E. coli, including the key factors for successful protein production, highlighting soluble protein production, and a comprehensive summary of the latest available and traditionally used gene fusion technologies. A special emphasis is given to the recently discovered Fh8 fusion system that can be used for soluble protein production, purification, and immunogenicity in E. coli. The number of existing fusion tags will probably increase in the next few years, and efforts should be taken to better understand how fusion tags act in E. coli. This knowledge will undoubtedly drive the development of new tailored-made tools for protein production in this bacterial system.
机译:现在,蛋白质已在各种微生物细胞工厂中广泛生产。大肠杆菌仍然是重组蛋白生产的主要宿主,但是作为细菌细胞,它也有其问题:外源蛋白聚集到不溶性包涵体中可能是大肠杆菌表达系统的主要限制因素。相反,大肠杆菌的成本,易用性和规模优势使其必须设计新的方法来改进宿主细胞中重组蛋白的生产。借助基因和蛋白质工程,可以设计出量身定制的新策略,以适应用户或过程的要求。基因融合技术已被广泛用于改善大肠杆菌中可溶性蛋白的生产和/或纯化,以及增强肽的免疫原性。新的融合伴侣不断涌现并补充了传统解决方案,例如,最近已经研究过的Fh8融合标签被评为最佳溶解度增强剂合作伙伴之一。在这篇综述中,我们概述了当前改善大肠杆菌中重组蛋白生产的策略,包括成功生产蛋白的关键因素,突出了可溶性蛋白生产以及最新可用和传统使用的基因融合技术的全面摘要。特别强调了最近发现的Fh8融合系统,该系统可用于大肠杆菌中的可溶性蛋白生产,纯化和免疫原性。未来几年中,现有融合标签的数量可能会增加,因此应努力更好地了解融合标签在大肠杆菌中的作用。这些知识无疑将推动针对该细菌系统中蛋白质生产的新型定制工具的开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号